Proteome Sciences PLC - London-based drug development services provider - Says it has repaid in full its outstanding loan and associated interest, totalling £824,424, to Vulpes Investment Management Private Ltd, as originally announced in July 2018 and amended in March last year.

In mid-May, Proteome Sciences said revenue for 2022 increased by 52% to £7.8 million, from £5.1 million in 2021. Biomarker services grew by 45% to £2.8 million and TMT revenue increased by 56% to £5.0 million. It said it was confident that progress over the recent years has created an ‘excellent’ platform for further development of the group.

Current stock price: 4.86 pence, up 2.5%

12-month change: up 26%

Copyright 2023 Alliance News Ltd. All Rights Reserved.